Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, April 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0842994/Social-Anxiety-Disorders-SAD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Social Anxiety Disorders (SAD) Therapeutics market. The report identifies the key trends shaping and driving the global Social Anxiety Disorders (SAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Social Anxiety Disorders (SAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Social Anxiety Disorders (SAD) Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Social Anxiety Disorders (SAD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Social Anxiety Disorders (SAD) Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Social Anxiety Disorders (SAD) Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Social Anxiety Disorders (SAD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Social Anxiety Disorders (SAD) Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Social Anxiety Disorders (SAD) Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Social Anxiety Disorders (SAD) Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Social Anxiety Disorders (SAD) Therapeutics - Introduction 7

2.1 Overview 7

2.1.1 Types of SAD 7

2.2 Etiology and Pathophysiology 7

2.3 Epidemiology 8

2.3.1 The US 8

2.3.2 Spain 8

2.3.3 Italy 8

2.3.4 Japan 8

2.3.5 Germany 8

2.3.6 France 8

2.3.7 Pharmaco-economic Burden 8

2.3.8 Quality of Life (QoL) 8

2.3.9 Morbidity 9

2.4 Symptoms 9

2.5 Diagnosis 9

2.5.1 Diagnostic Criteria for SAD Defined by DSM-IV 9

2.5.2 Measurement Scales 10

2.6 Treatment and Management Pattern 10

2.6.1 Psychological Treatment 10

2.6.2 Pharmacologic Treatment 11

2.7 Referral Pathway 12

2.8 GlobalData Pipeline Report Guidance 13

3 SAD Therapeutics - Market Characterization 14

3.1 Overview 14

3.2 SAD Therapeutics Market Size (2006-2011) - Global 14

3.3 SAD Therapeutics Market Forecast (2011-2019) - Global 16

3.4 SAD Therapeutics Market Size (2006-2011) - The US 17

3.5 SAD Therapeutics Market Forecast (2011-2019) - The US 18

3.6 SAD Therapeutics Market Size (2006-2011) - France 19

3.7 SAD Therapeutics Market Forecast (2011-2019) - France 20

3.8 SAD Therapeutics Market Size (2006-2011) - Germany 21

3.9 SAD Therapeutics Market Forecast (2011-2019) - Germany 22

3.10 SAD Therapeutics Market Size (2006-2011) - Italy 23

3.11 SAD Therapeutics Market Forecast (2011-2019) - Italy 24

3.12 SAD Therapeutics Market Size (2006-2011) - Spain 25

3.13 SAD Therapeutics Market Forecast (2011-2019) - Spain 26

3.14 SAD Therapeutics Market Size (2006-2011) - The UK 27

3.15 SAD Therapeutics Market Forecast (2011-2019) - The UK 28

3.16 SAD Therapeutics Market Size (2006-2011) - Japan 29

3.17 SAD Therapeutics Market Forecast (2011-2019) - Japan 30

3.18 Drivers and Barriers 31

3.18.1 Drivers for the SAD Therapeutics Market 31

3.18.2 Barriers for the SAD Therapeutics Market 31

3.19 Opportunity and Unmet Needs 31

3.20 Key Takeaway 32

4 SAD Therapeutics Market - Competitive Assessment 33

4.1 Overview 33

4.2 Strategic Competitor Assessment 33

4.3 Product Profile for the Major Marketed Products in the SAD Therapeutics Market 34

4.3.1 SSRIs 34

4.3.2 SNRIs 34

4.3.3 Benzodiazepines 36

4.3.4 Monoamine Oxidase Inhibitors 37

4.4 Key Takeaway 37

5 SAD Therapeutics - Pipeline Assessment 38

5.1 Overview 38

5.2 Strategic Pipeline Assessment 38

5.3 Pipeline by Phases of Development 38

5.3.1 SAD Therapeutics-Phase II Pipeline 38

5.3.2 SAD Therapeutics- Phase I Pipeline 39

5.4 SAD Therapeutics Market - Clinical Pipeline by Mechanism of Action. 39

5.5 Technology Trends Analytic Framework 40

5.6 Promising Drugs under Clinical Development 41

5.7 Profiles of Promising Drugs 42

5.7.1 CXB722 42

5.7.2 PH94B 42

5.7.3 TGW00AA 43

5.8 Key Takeaway 44

6 SAD Therapeutics - Clinical Trials Mapping 45

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 45

6.2 Clinical Trials by Phase 46

6.3 Clinical Trials by Trial Status 47

6.4 Prominent Sponsors 48

6.5 Top Companies Participating in Therapeutics Clinical Trials 50

7 SAD Therapeutics - Strategic Assessment 51

7.1 Key Events Impacting the Future Market 51

7.2 Future Market Competition Scenario 51

8 SAD Therapeutics - Future Players 53

8.1 Introduction 53

8.2 Company Profiles 54

8.2.1 CeNeRx BioPharma 54

8.2.2 Fabre-Kramer Pharmaceuticals, Inc 54

8.2.3 Pherin Pharmaceuticals 55

8.3 Other Companies in the SAD Therapeutics Market 56

9 SAD Therapeutics - Licensing and Partnership Deals 57

10 Appendix 58

10.1 Market Definitions 58

10.2 Abbreviations 58

10.3 Methodology 59

10.3.1 Coverage 59

10.3.2 Secondary Research 59

10.3.3 Forecasting 60

10.3.4 Primary Research 62

10.3.5 Expert Panel Validation 63

10.4 Contact Us 63

10.5 Disclaimer 63

10.6 Bibliography 63

List of Tables

Table 1: FDA and EMEA Approved Medications for the Treatment of SAD 12

Table 2: SAD Therapeutics Market, Global, Revenue ($m), 2006-2011 15

Table 3: SAD Therapeutics Market, Global, Forecast ($m), 2011-2019 16

Table 4: SAD Therapeutics Market, The US, Revenue ($m), 2006-2011 17

Table 5: SAD Therapeutics Market, The US, Forecast ($m), 2011-2019 18

Table 6: SAD Therapeutics Market, France, Revenue ($m), 2006-2011 19

Table 7: SAD Therapeutics Market, France, Forecast ($m), 2011-2019 20

Table 8: SAD Therapeutics Market, Germany, Revenue ($m), 2006-2011 21

Table 9: SAD Therapeutics Market, Germany, Forecast ($m), 2011-2019 22

Table 10: SAD Therapeutics Market, Italy, Revenue ($m), 2006-2011 23

Table 11: SAD Therapeutics Market, Italy, Forecast ($m), 2011-2019 24

Table 12: SAD Therapeutics Market, Spain, Revenue ($m), 2006-2011 25

Table 13: SAD Therapeutics Market, Spain, Forecast ($m), 2011-2019 26

Table 14: SAD Therapeutics Market, The UK, Revenue ($m), 2006-2011 27

Table 15: SAD Therapeutics Market, The UK, Forecast ($m), 2011-2019 28

Table 16: SAD Therapeutics Market, Japan, Revenue ($m), 2006-2011 29

Table 17: SAD Therapeutics Market, Japan, Forecast ($m), 2011-2019 30

Table 18: Treatment-Emergent Adverse Event Incidence in Short-Term Placebo-Controlled Effexor XR Clinical Trials in SAD Patients 35

Table 19: SAD Therapeutics-Phase II Pipeline 38

Table 20: SAD Therapeutics-Phase I Pipeline 39

Table 21: SAD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 41

Table 22: SAD Therapeutics Market, Number of Clinical Trials by Region, 2011 45

Table 23: SAD Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 46

Table 24: SAD Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011 47

Table 25: SAD Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011 49

Table 26: SAD Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011 50

Table 27: CeNeRx BioPharma - CNS Pipeline Products, 2011 54

Table 28: CeNeRx BioPharma - SAD Pipeline Products, 2011 54

Table 29: Fabre-Kramer Pharmaceuticals - CNS Pipeline Products, 2011 55

Table 30: Fabre-Kramer Pharmaceuticals - SAD Pipeline Products, 2011 55

Table 31: Pherin Pharmaceuticals - CNS Pipeline Products, 2011 55

Table 32: Pherin Pharmaceuticals - SAD Pipeline Products, 2011 55

Table 33: SAD Therapeutics Market - Future Players, 2011 56

Table 34: SAD Therapeutics, Global, Deals, 2009-2011 57

List of Figures

Figure 1: SAD Treatment Options 11

Figure 2: Referral Pathway for SAD 12

Figure 3: SAD Therapeutics Market, Global, Revenue ($m), 2006-2011 14

Figure 4: SAD Therapeutics Market, Global, Forecast ($m), 2011-2019 16

Figure 5: SAD Therapeutics Market, The US, Revenue ($m), 2006-2011 17

Figure 6: SAD Therapeutics Market, The US, Forecast ($m), 2011-2019 18

Figure 7: SAD Therapeutics Market, France, Revenue ($m), 2006-2011 19

Figure 8: SAD Therapeutics Market, France, Forecast ($m), 2011-2019 20

Figure 9: SAD Therapeutics Market, Germany, Revenue ($m), 2006-2011 21

Figure 10: SAD Therapeutics Market, Germany, Forecast ($m), 2011-2019 22

Figure 11: SAD Therapeutics Market, Italy, Revenue ($m), 2006-2011 23

Figure 12: SAD Therapeutics Market, Italy, Forecast ($m), 2011-2019 24

Figure 13: SAD Therapeutics Market, Spain, Revenue ($m), 2006-2011 25

Figure 14: SAD Therapeutics Market, Spain, Forecast ($m), 2011-2019 26

Figure 15: SAD Therapeutics Market, The UK, Revenue ($m), 2006-2011 27

Figure 16: SAD Therapeutics Market, The UK, Forecast ($m), 2011-2019 28

Figure 17: SAD Therapeutics Market, Japan, Revenue ($m), 2006-2011 29

Figure 18: SAD Therapeutics Market, Japan, Forecast ($m), 2011-2019 30

Figure 19: Opportunity and Unmet Need in the SAD Therapeutics Market, 2011 32

Figure 20: Strategic Competitor Assessment of the Major Marketed Products in SAD, 2011 33

Figure 21: SAD Therapeutics Pipeline by Phases of Clinical Development (%), 2011 38

Figure 22: SAD Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011 39

Figure 23: Technology Trends Analytic Framework of the SAD Therapeutics Pipeline, 2011 40

Figure 24: Technology Trends Analytic Framework of the SAD Therapeutics Pipeline - Description, 2011 41

Figure 25: CXB722 Clinical Trial Details 42

Figure 26: PH94B Clinical Trial Details 43

Figure 27: TWG00AA Clinical Trial Details 43

Figure 28: SAD Therapeutics Market, Number of Clinical Trials by Region, 2011 45

Figure 29: SAD Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 46

Figure 30: SAD Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011 47

Figure 31: SAD Therapeutics Market, Global, Clinical Trials by Overall Sponsors (%), 2011 48

Figure 32: SAD Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011 49

Figure 33: SAD Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011 50

Figure 34: SAD Therapeutics Market, Drivers and Restraints, 2011 51

Figure 35: Implications for Future Market Competition in the SAD Therapeutics Market, 2011 52

Figure 36: SAD Therapeutics Market, Clinical Pipeline by Company, 2011 53

Figure 37: GlobalData Market Forecasting Model 62

Companies mentioned

CeNeRx BioPharma

Fabre-Kramer Pharmaceuticals, Inc

Pherin Pharmaceuticals

To order this report:

Therapy Industry: Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker